PDL BioPharma just came out with a new prospectus, available here. This is an SEC requirement for firms looking to issue certain types of securities. An excerpt of the prospectus is provided below:
EX-1.1 2 a20160606s3docfor424b5.htm PROSPECTUS S-3 Document PROSPECTUSPDL BioPharma, Inc.$250,000,000Debt SecuritiesCommon StockPreferred StockDepositary SharesWarrantsStock Purchase ContractsStock Purchase UnitsUnits of these Securities__________________We may, from time to time, offer to sell debt securities, common stock, preferred stock, depositary shares, warrants, stock purchase contracts, stock purchase units, or units of any of these securities. The aggregate initial offerin g price of all securities sold under this prospectus will not exceed $250,000,000. We will provide specific terms of these securities in supplements to this prospectus at the time we offer or sell any of these securities. This prospectus may not be used to sell securities unless accompanied by a prospectus supplement. You should read this prospectus and the applicable prospectus supplement carefully before you invest.Our common stock is listed on the NASDAQ Global Select Market under the symbol “PDLI.” On June 9, 2016, the closing price of our common stock as reported by the NASDAQ Global Select Market, was $3.27 per share.Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading “Risk Factors” on page 4 of this prospectus, in our most recent Annual Report on Form 10-K, our most recent Quarterly Report on Form 10-Q and in other documents that we subsequently file with the Securities and Exchange Commission, which are incorporated by reference into this prospectus, and in the applicable prospectus supplement we will deliver with this prospectus and in the documents incorporated herein and therein by reference.__________________Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.This prospectus is dated J
The above information was disclosed in a filing to the SEC. To see the filing, click here.
To receive a free e-mail notification whenever PDL BioPharma makes a similar move, sign up!
Other recent filings from the company include the following:
Current report, items 7.01 and 9.01
- Nov. 14, 2017
PDL BioPharma Just Filed Its Quarterly Report: 2. Net Income per Sh... - Nov. 13, 2017
Notification of inability to timely file Form 10-Q or 10-QSB - Nov. 13, 2017
Pdl Biopharma’S Proposal To Acquire Neos Therapeutics Expires Today; - Nov. 8, 2017
PDL: Cook Williams Communications, Inc - Nov. 2, 2017